Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Core Insights - Tevogen Bio Holdings Inc. has been recognized in the 2025 New Jersey Power List by NJBIZ for its influence on the state's economic and innovation landscape [1][2] Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing AI and precision T cell therapy platforms [4] - The company is committed to advancing life-saving therapies across various therapeutic areas and aims to broaden patient access through innovative healthcare solutions [7] Technological Advancements - The ExacTcell™ platform is a key innovation, with a pipeline addressing infectious diseases, oncology, and neurology [2][5] - Tevogen.AI technology is designed to enhance drug development by improving target detection and clinical trial design, leveraging cloud services from major tech providers [6] Financial Projections - Tevogen anticipates approximately $1 billion in first-year specialty-care revenue and a cumulative five-year revenue forecast of $18–22 billion [2] Expansion and Commitment - The company is expanding its operations with a new 17,428-square-foot manufacturing facility and headquarters, which will centralize R&D and regulatory functions [3]